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Articles
Selective dorsal rhizotomy in ambulant children with 
cerebral palsy: an observational cohort study
Jennifer Summers, Bola Coker, Saskia Eddy, Maria Elstad, Catey Bunce, Elli Bourmpaki, Mark Pennington, Kristian Aquilina, Stephanie Cawker, 
Richard Edwards, John Goodden, Sally Hawes, Kate McCune, Benedetta Pettorini, Jennifer Smith, Christine Sneade, Michael Vloeberghs, 
Hannah Patrick, Helen Powell, Christopher Verity, Janet L Peacock, for the Selective Dorsal Rhizotomy Steering Committee*
Summary
Background Selective dorsal rhizotomy (SDR) is an irreversible surgical procedure involving the division of selected 
sensory nerve roots, followed by intensive physiotherapy. The aim is to improve function and quality of life in children 
with cerebral palsy and a Gross Motor Function Classification System (GMFCS) level of II or III (walks with or 
without assistive devices, respectively). We assessed gross motor function before and after SDR and postoperative 
quality of life in a study commissioned by NHS England.
Methods We did a prospective observational study in five hospitals in England who were commissioned to perform 
SDR on children aged 3–9 years with spastic diplegic cerebral palsy. The primary outcome was score changes in the 
66-item Gross Motor Function Measure (GMFM-66) and seven domains of the Cerebral Palsy Quality of Life 
Questionnaire ([CP-QoL] social wellbeing and acceptance, feelings about functioning, participation and physical 
health, emotional wellbeing and self-esteem, access to services, family health, and pain and impact of disability) from 
before to 24 months after SDR.
Findings From Sept 4, 2014, to March 21, 2016, 137 children underwent SDR. The mean age was 6·0 years (SD 1·8). 
The mean GMFM-66 score increased after SDR with an annual change of 3·2 units (95% CI 2·9 to 3·5, n=137). Of 
the seven CP-QoL domains, five showed significant improvements over time: feelings about functioning mean 
annual change 3·0 units (95% CI 2·0 to 4·0, n=133), participation and physical health 3·9 units (2·5 to 5·3, n=133), 
emotional wellbeing and self-esteem 1·3 units (0·2 to 2·3, n=133), family health 2·0 units (0·7 to 3·3, n=132), and 
pain and impact of disability –2·5 units (–3·9 to –1·2, n=133). 17 adverse events were reported in 15 children, of 
which none were severe and 15 (88%) resolved.
Interpretation SDR improved function and quality of life in the 24 months after surgery in children with cerebral 
palsy classified as GMFCS levels II and III. On the basis of these findings, an interim national policy decision was 
made that SDR would be funded for eligible children in England from 2018.
Funding National Institute for Health and Care Excellence, National Institute for Health Research Biomedical 
Research Centre, NHS England.
Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
The worldwide incidence of cerebral palsy is 2–3 per 
1000 livebirths,1 and approximately 80% of affected 
children have spasticity in their lower limbs.2 With no 
cure, treatment options aim to alleviate symptoms and 
improve quality of life. Medical treatments include 
intramuscular injections of botulinum toxin, oral 
baclofen, or both, to relieve muscle stiffness, anti-
inflammatories for pain, and orthotic devices and 
physiotherapy to aid walking. Surgical interventions 
include operations on bony or soft tissue, orthopaedic 
surgery to restore lower-limb alignment, and neurosurgery 
such as selective dorsal rhizotomy (SDR).3 SDR is an 
irreversible neurosurgical procedure in which sensory 
nerve roots are divided. The aim is to reduce spasticity in 
the lower limbs and improve gross motor function and 
quality of life.4–7 Intensive physiotherapy is provided for 
several months after SDR.4
Evidence from randomised controlled trials (RCTs) 
relating to SDR is limited. Three RCTs were done in 
Canada and the USA but were published between 1997 
and 1998.6,8,9 These compared SDR plus physiotherapy 
with physiotherapy alone. Data from the 90 children 
assessed were summarised in a meta-analysis in 2002,10 
which showed consistent overall improvement in 
function in children receiving SDR compared with 
those receiving physiotherapy alone (2·7 unit mean 
difference in scores in the 66-item Gross Motor Function 
Measure (GMFM-66) units at a median follow-up of 
12 months; appendix). The RCTs were well reported 
and included robust methods of randomisation and 
allocation concealment, but follow-up was short 
(9–12 months) and no data were collected on quality of 
life. Two of the three RCTs reported no adverse events8,9 
and the third reported one spinal epidural abscess and 
one transient urinary retention.6
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SDR has not been routinely available via the National 
Health Service (NHS) in England and has been possible 
to obtain only through individual funding requests.11 
Although the findings of several cohort studies (including 
the RCTs) have suggested positive long-term outcomes 
after SDR,5,6,8–10,12–14 NHS England judged the evidence 
base to be inadequate to permit universal funding 
because studies were more than 20 years old and quality 
of life was not measured in the RCTs4 and requested 
further evidence for the effects of SDR on longer-term 
outcomes. A further RCT was not possible in the UK 
because of the lack of equipoise among physicians and 
parents who strongly believed that there was a need for 
SDR. Therefore, in 2014, NHS England commissioned a 
prospective evaluation of SDR in a series of eligible 
children with standardised outcomes and 2 years of 
follow-up. We report on the gross motor function and 
quality of life outcomes after SDR.
Methods
Study design and oversight
Five NHS paediatric neurosurgical centres in England 
(appendix) were commissioned by NHS England 
Commissioning through Evaluation programme to 
provide a package of care according to a standardised 
protocol. The Commissioning through Evaluation 
programme enables a limited number of patients to 
access treatments that are promising but not yet 
universally funded by the NHS to allow new data to be 
collected on clinical outcomes and patients’ experiences. 
The SDR care package included surgery and 
physiotherapy for up to 24 months for eligible children. 
Data were collected in the Research Electronic Data 
Capture application15 and outcomes were reported to a 
national database.4 Planning and oversight of the 
study was provided by a multidisciplinary SDR steering 
committee, which included clinical and academic 
experts, representatives of patients, and NHS England 
commissioners. The study did not include a control 
group and, therefore, age-specific and severity-specific 
normalised GMFM-66 centiles developed in Canada and 
based on children who had not had SDR were used to 
provide comparative data.16–18
Ethics approval for the collation of data and its 
subsequent analysis was given by the UK Health 
Research Authority. Written informed consent for data 
collection and analysis was obtained from the parents or 
primary caregivers for all children.
Selection of patients
Each centre had a multidisciplinary team that selected 
children for inclusion in the study according to a rigorous 
Research in context
Evidence before this study
Selective dorsal rhizotomy (SDR) for children with cerebral palsy 
has not been routinely available via the National Health Service 
(NHS) in England. Although some international evidence 
indicates positive long-term outcomes, NHS England judged 
that the evidence base was insufficient to support universal 
funding. We searched the Cochrane database, EMBASE, PubMed, 
Web of Science, and grey literature on Oct 15, 2018, for 
randomised controlled trials that compared SDR and non-SDR 
outcomes in patients with cerebral palsy. We found three small 
randomised controlled trials that involved 90 patients. 
A meta-analysis provided evidence of improved mean gross 
motor function 9–12 months after SDR with no suggestion of 
harm. All three studies, however, were done in the 1990s, since 
when surgical techniques have changed, and they captured no 
data on quality of life or long-term follow-up. A new 
randomised trial was impossible in the UK because of the lack of 
clinical equipoise among physicians and patients (including 
parents), yet firmer evidence of benefit without harm was 
needed to inform a policy decision. Therefore, in 2014, NHS 
England commissioned a robust evaluation of SDR with 
standardised outcomes and with 24 months of follow-up after 
surgery in five NHS paediatric neurosurgical centres in England.
Added value of this study
This assessment of SDR followed by intensive physiotherapy 
was done in a large contemporary group of 137 children. 
The study obtained prospective data on a wide range of 
validated outcomes collected in a standardised way, and 
particularly assessed gross motor function (66-item Gross 
Motor Function Measure) and quality of life (Cerebral Palsy 
Quality of Life Questionnaire for Children parent version), 
including pain and adverse events, over the 2-year follow-up. 
Assessment of multiple data points allowed patients’ 
trajectories to be modelled statistically and showed clear 
improvement in function and quality of life, including 
reduced pain, with no evidence of harm. Furthermore, 
we compared our data with age-specific and severity-specific 
norm centiles for gross motor function that were developed 
in Canada for children with cerebral palsy who had not 
had SDR. These showed that the observed benefit of SDR 
among children in this study exceeded the expected function 
without SDR.
Implications of all the available evidence
This evaluation provides robust evidence that SDR plus 
intensive physiotherapy improves gross motor function, quality 
of life, and pain to greater degrees than would be expected 
without SDR. The evidence was used to inform a policy review 
in 2018 by NHS England, which resulted in funding of SDR 
being supported for eligible children aged 3–9 years with 
cerebral palsy.
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process. The teams were experienced in the delivery of 
SDR surgery and other accepted antispasticity treatments 
and the neurosurgeons performing surgery had previous 
experience and training in the SDR procedure. The 
assessment process was designed to balance functional 
abilities and impairments. A minimum list of assessments 
was provided by NHS England to be done for each patient 
before and after surgery (appendix).
Eligible children had spastic diplegic cerebral palsy that 
limited functional abilities and sufficient strength to 
rehabilitate after SDR surgery. Other inclusion criteria 
were age 3–9 years; MRI confirmation of no damage to 
key areas of the brain controlling posture or coordination 
(eg, lesions in the basal ganglia or cerebellum, which are 
associated with dyskinetic or ataxic cerebral palsy types) 
and typical cerebral palsy changes (white-matter damage 
of immaturity, namely periventricular leukomalacia); 
Gross Motor Function Classification System (GMFCS)19 
level II (walks without assistive devices) or III (walks 
with assistive devices); no evidence of genetic or 
neurological progressive illness; mild to moderate lower-
limb weakness with ability to maintain antigravity 
postures, no significant scoliosis or hip dislocation 
(Reimer’s index20 <40%); confirmed financial or resource 
commitment for community-based postoperative physio- 
therapy; and no other relevant medical or personal 
contraindications. Patients with progressive neurological 
conditions and those with dystonia were excluded 
(appendix).
Treatment and follow-up
SDR was performed with a single-level laminectomy or 
laminoplasty approach with neurophysiology-guided 
partial section of the dorsal (sensory) nerve roots. 
Intraoperative neurophysiology was mandated to guide 
the selection of the nerve rootlets being divided. Each 
nerve root from L1 to S1 was divided into smaller portions 
(rootlets) of approximately equal size, which were tested 
with neurophysiology to elicit a reflex motor response. 
The responses were recorded and graded for extent 
of spread to adjacent myotome levels.21 The rootlets 
responsible for the greatest neurophysiology responses 
were cut. The physiotherapy regimen after surgery was 
specified and recommended for 24 months after discharge 
from hospital. Follow-up assessments were done at 
4–6 months, 12 months, and 24 months after surgery.
Outcomes
The primary outcomes were change in gross motor 
function, measured with the GMFM-66 (a 66-item tool, 
with higher scores representing greater motor function, 
which is measured in five key motor domains: lying and 
rolling; sitting; crawling and kneeling; standing; and 
walking, running and jumping), which has been 
validated for assessment of children with cerebral 
palsy;22,23 change in GMFM-66 centiles measured with 
the normalised version of GMFM-66, which is adjusted 
for age and GMFCS level; change in quality of life 
measured with seven domains of the parent or caregiver 
version of the Cerebral Palsy Quality of Life Questionnaire 
for Children ([CP-QoL] social wellbeing and acceptance, 
feelings about functioning, participation and physical 
health, emotional wellbeing and self-esteem, access to 
services, family health, and pain and impact of 
disability);24 and adverse events, measured for intensity, 
duration, outcomes, and relation to SDR. GMFCS was 
used to categorise the severity of involvement,19 and 
we used GMFM-66 as an objective assessment of 
neurological impairment during follow-up. Prespecified 
secondary outcomes were assessment of spasticity using 
the Modified Ashworth Scale,25 the Boyd and Graham 
Scale,26 gait analyses, and physiotherapy assessments 
(appendix). 
Statistical analysis
The study was originally intended to include 163 patients, 
but due to a delay in the launch of the Commissioning 
through Evaluation programme, the overall number 
treated was 137. GMFM-66 scores, GMFM-66 centiles, and 
CP-QoL scores were used to follow patients’ trajectories 
based on within-patient changes from before to 24 months 
after SDR. We used a linear mixed model in which the 
patient was the random effect and time was modelled 
using time from SDR surgery to each assessment. 
Difference in changes over time was assessed by GMFCS 
level by fitting an interaction term in the model with a 
likelihood ratio test. All results were scaled to mean annual 
change with 95% CIs. Model fit and model assumptions 
were checked with residual plots. Changes in the Modified 
Ashworth Scale, Boyd and Graham Scale, and Gait Profile 
Score over time were analysed with non-parametric tests. 
Sensitivity analysis of all children and all children 
excluding the three children aged older than 9 years at the 
time of SDR surgery found no material difference in 
results. To account for the multiplicity of outcomes and 
sensitivity analysis, we adjusted for multiple testing using 
a Bonferroni correction for the eight-variable composite 
outcome of GMFM-66 score and the seven CP-QoL 
domain scores. The modified cutoff for significance for 
this composite outcome was 0·0064 (1 – 0·950·125). Stata 
version 15 was used for all statistical analyses.
Role of the funding source
The funders of the study had a role in the study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had full 
access to the data and had final responsibility for the 
decision to submit for publication. 
Results
Between Sept 4, 2014, and March 21, 2016, 137 patients 
underwent SDR in the five study centres. No patients 
withdrew from the programme, but one patient did not 
complete the final assessment at 24 months. Most 
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patients (61%) were boys and had GMFCS level III (62%; 
table 1). The mean length of hospital stay following SDR 
for all patients was 19·3 days (SD 7·1), although the time 
varied by centre (range 3–39 days). All patients had nerve 
rootlets cut during SDR in L2–S1, and 125 had rootlets 
cut in L1 (appendix). For most patients the percentage 
of rootlets cut for L1–S1 was between 60% and less 
than 70%.
GMFM-66 scores increased in almost all children from 
before surgery to 24 months after surgery (figure, 
appendix). Mean annual increases were significant 
(table 2), with the overall increase being 3·2 units per year 
(95% CI 2·9–3·5, p<0·0001). The estimated increase was 
higher in patients with GMFCS level II than in those with 
GMFCS level III (table 2), which was a significant 
difference (pinteraction=0·006). Similarly, significant changes 
were seen for normalised GMFM-66 centiles over 2 years 
(table 2). The estimated norms for GMFM-66 calculated 
from the Canadian cohort who had not undergone SDR 
were lower than the modelled change and entirely below 
the 95% CIs estimated from the current SDR data. This 
was true for all children and in the GMFCS II and III 
subgroups (appendix).
The CP-QoL results for all children improved 
significantly over 2 years for all domains assessed except 
social wellbeing and acceptance, emotional wellbeing and 
self-esteem, and access to services, although these did 
also improve slightly (table 2).
17 adverse events were reported for 15 children, with 
most having one event only (table 3). All but two were 
thought to be definitely or probably related to SDR, but 
none was a serious safety concern. The most common 
events were wound infection and persisting dysaesthesia 
in the feet and legs. No severe adverse events were 
reported and most resolved.
The mean Gait Profile Score improved significantly 
from before to 24 months after SDR (p<0·001). Physio-
therapists reported that the post-SDR physiotherapy 
All patients (n=137)
Baseline characteristics
Age at SDR (years)
Mean (SD) 6·0 (1·8)
Range 3–9*
Boys 83/137 (61%)
Girls 54/137 (39%)
GMFCS level
II 52/137 (38%)
III 85/137 (62%)
Height before SDR (cm)
Mean (SD) 112·1 (12·7)
Range 87·0–139·0
Weight before SDR (kg)
Mean (SD) 21·3 (7·0)
Range 11·4–45·5
Body-mass index before SDR (kg/m²)
Mean (SD) 16·9 (4·0)
Range 12·8–48·9
Body-mass index centile before SDR
Mean (SD) 55·2 (31·9)
Range 0–100
Pregnancy duration (weeks)
Mean (SD) 32 (4·0)
Range 26–42
Birthweight (kg)
Mean (SD) 1·9 (0·8)
Range 0·8–4·2
Medication in previous 6 months
Oral baclofen 23/129 (18%)
Diazepam 3/129 (2%)
Botulinum toxin 15/129 (12%)
Previous surgery
Gastrocnemius or heel cord 0/129
Bone 2/129 (2%)
Adductor 0/129
Hamstring 1/129 (1%)
SEN or education, health, and care plan
Learning difficulties 19/137 (14%)
Behaviour, emotional, and social 
difficulty
20/137 (15%)
Speech, language, and 
communication needs
6/137 (4%)
Autistic spectrum disorder 5/137 (4%)
Hearing impairment 1/137 (1%)
Visual impairment 4/137 (3%)
Physical disability other than cerebral 
palsy
17/137 (12%)
No SEN disability 28/137 (20%)
No SEN support 57/137 (42%)
(Table 1 continues in next column)
All patients (n=137)
(Continued from previous column)
Operative characteristics
Length of stay in hospital after SDR (days)
Mean (SD) 19·3 (7·1)
Range 3–39
Intraoperative neurophysiology 137/137 (100%)
Sphincter monitoring 114/122 (93%)
Mean proportion of nerve rootlet cut 
from L1 to S1 left and right†
64·6
Range of the mean proportion of the 
centre of nerve rootlet cut from 
L1 to S1 left and right†
57·1–66·0
SDR=selective dorsal rhizotomy. GMFCS=Gross Motor Function Classification 
System. SEN=special educational needs. *Three children were aged 9 years at the 
time of the assessment before SDR and 10 years at time of surgery. A sensitivity 
analysis of all children and excluding the three children aged older than 9 years at 
the time for surgery showed no difference in results. †Excludes rootlets with 
0% cut.
Table 1: Baseline and operative characteristics
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recommendations had been implemented for 126 (95%) 
of 134 children at 24 months.
Five of the eight composite variables fulfilled the 
criterion for significance of p<0·0064, and even with 
adjustment for multiple testing, the primary outcomes 
were significant.
Discussion
This prospective multicentre study followed up children 
with spastic diplegia for 24 months after they underwent 
SDR and found consistent improvements in patients’ 
outcomes that increased annually over this period. In 
particular, GMFM-66 scores and normalised GMFM-66 
centiles increased significantly with reasonably narrow 
95% CIs. The estimated increase in GMFM-66 scores 
was higher in children classified as GMFCS level II than 
in those classified as GMFCS level III. All changes were 
greater than those that would be expected without SDR,16–
18 validating the improvement in function. The findings 
were also consistent with a meta-analysis of RCTs, which 
showed a greater improvement in mean GMFM-66 with 
SDR plus physiotherapy than with physiotherapy alone 
with median follow-up of 12 months.10 Compared with 
the GMFM-66 centiles for children who had not 
undergone SDR, those in our study showed a similar 
trend towards an improvement from before to 24 months 
after SDR, with greater change seen in children classified 
as GMFCS level III than in those classified as GMFCS 
level II. Specifically, quality of life improved in terms of 
feelings about functioning, participation and physical 
health, emotional wellbeing and self-esteem, pain and 
impact of disability, and family health. The pain score 
was reduced by 2·5 units per year, which although a 
small change, was significant. These findings are 
consistent with previously reported improved quality of 
life 20–28 years after SDR14 and reduced pain after 
17 years.5
No serious safety concerns related to SDR occurred in 
the 24-month postoperative follow-up period. SDR 
surgery and postoperative care have evolved since the 
RCTs,6,8,9 but they also showed no short-term safety 
concerns. Nevertheless, complications following SDR 
have been reported in other studies. Grunt and 
colleagues7 did a systematic review of 21 observational 
studies among which six studies reported spinal 
abnormalities, although no strong association was 
found with SDR. In a study with 10 years of follow-up, 
all 19 patients assessed had transient flexor spasm in 
the calves and hypotonia of the legs after SDR, one 
patient had transient urinary incontinence, and ten 
patients had hyperaesthesia.27
This study has several strengths. First, it represents a 
contemporary clinical series of prospectively enrolled 
patients with defined characteristics who underwent 
SDR in five paediatric neurosurgical centres. All 
the children underwent rigorous and standardised 
assessments before and after surgery. In 2017, NHS 
England requested an interim analysis of results to feed 
into policy discussions. All children were included in 
these analyses, which drew upon the primary outcomes 
and formed part of the evidence base used to support the 
introduction of SDR into specialised NHS com-
missioning in July, 2018, pending completion of the final 
analyses.28 Second, this study included a larger study 
sample than previous studies, which allowed prospective 
collection of a wide range of specific clinical data. Third, 
the primary outcomes of gross motor function and 
quality of life were measured with validated instruments 
that are widely used in research. Fourth, we used linear 
mixed models that account for the longitudinal 
measurements and allow the inclusion of all patients in 
the analyses despite a small number of missing values.
The main limitation of the study is the absence of a 
comparison group, which means that direct comparisons 
of outcomes cannot be made in children who did and did 
not undergo SDR. Given the evidence for the effectiveness 
of SDR from the 1990s,6,8,9 a further trial is unlikely to be 
acceptable and, therefore, no concurrent comparator 
patients can be recruited in England. To mitigate this 
Figure: Observed trajectories of gross motor function for all patients by 
disease severity
137 children were assessed at baseline and all points before 24 months. (A) Gross 
Motor Function Classification System level II. (B) Gross Motor Function 
Classification System level III. GMFM-66=66-item Gross Motor Function Measure. 
SDR=selective dorsal rhizotomy.
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limitation, we normalised our raw GMFM-66 scores based 
on an external standard. Another limitation is that the 
length of follow-up was 24 months, which does not allow 
assessment of outcomes into young adulthood. However, 
several long-term cohort studies with different groups of 
patients and outcomes suggest sustained (15–28 years) 
positive effects of SDR on quality of life5,14 and function.12,13
The clinical interpretation of the size of change in 
GMFM-66 is challenging because to our knowledge 
there is no established consensus on the minimum 
clinically important difference. The annual change of 
2·3 GMFM-66 units we calculated is in broad agreement 
with the mean improvement in GMFM-66 reported by 
Bolster and colleagues,29 who found a change of 7·6 units 
after 5 years in 19 children. Further comparison is 
difficult due to differences in follow-up periods and 
populations of patients. However, this finding, along 
with the accompanying improvement in quality of life in 
our study (including reduction in pain) and improvement 
in gross motor function beyond that expected without 
SDR, strongly support the effectiveness of SDR.
Our study enrolled children aged 3–9 years with 
GMFCS levels II or III, which is estimated to occur in 
15% of children with cerebral palsy and a diagnosis 
Before SDR 24 months after SDR Modelled mean change per year (95% CI)
GMFM-66*
GMFCS level II 69·0 (7·9), n=52 77·6 (8·9), n=51 3·8 (3·2 to 4·2, p<0·0001)
GMFCS level III 52·8 (4·6), n=85 58·8 (7·5), n=82 2·9 (2·5 to 3·2, p<0·0001)
All patients 59·0 (9·9), n=137 66·0 (12·2), n=133 3·2 (2·9 to 3·5, p<0·0001)
Normalised GMFM-66 centiles†
GMFCS level II 67·3 (28·0), n=51 78·8 (22·2), n=46 3·7 (2·0 to 5·2, p<0·0001)
GMFCS level III 54·6 (21·1), n=85 69·7 (23·3), n=81 7·3 (6·0 to 8·7, p<0·0001)
CP-QoL Child domains‡
Social wellbeing and acceptance§
GMFCS level II 82·4 (15·3), n=51 84·7 (15·6), n=49 0·7 ( –0·9 to 2·3, p=0·405)
GMFCS level III 81·5 (12·7), n=82 82·1 (11·3), n=79 –0·01 ( –1·1 to 1·1, p=0·979)
All patients 81·8 (13·7), n=133 83·1 (13·1), n=128 0·3 (–0·7 to 1·2, p=0·580)
Feelings about functioning§
GMFCS level II 74·2 (16·4), n=51 81·2 (14·0), n=48 2·4 ( 0·6 to 4·2, p=0·008)
GMFCS level III 68·1 (11·3), n=82 76·5 (12·1), n=79 3·4 ( 2·3 to 4·5, p<0·0001)
All patients 70·5 (13·8), n=133 78·3 (13·0), n=128 3·0 (2·0 to 4·0, p<0·0001)
Participation and physical health§
GMFCS level II 59·1 (17·4), n=51 70·6 (18·8), n=49 4·1 ( 1·7 to 6·6, p=0·001)
GMFCS level III 53·7 (16·6), n=82 63·6 (17·3), n=79 3·7 ( 2·0 to 5·5, p<0·0001)
All patients 55·7 (17·1), n=133 66·3 (18·1), n=128 3·9 (2·5 to 5·3, p<0·0001)
Emotional wellbeing and self-esteem§
GMFCS level II 77·8 (18·5), n=51 82·7 (16·7), n=49 1·5 ( –0·4 to 3·5, p=0·121)
GMFCS level III 78·5 (10·7), n=82 82·1 (11·3), n=79 1·1 ( –0·1 to 2·3, p=0·072)
All patients 78·2 (14·2), n=133 82·3 (13·6), n=128 1·3 (0·2 to 2·3, p=0·018)
Access to services§
GMFCS level II 47·4 (13·0), n=51 49·7 (11·9), n=49 0·5 ( –1·2 to 2·3, p=0·563)
GMFCS level III 48·5 (11·3), n=82 52·1 (14·2), n=79 0·5 ( –0·9 to 1·9, p=0·465)
All patients 48·1 (11·9), n=133 51·2 (13·3), n=128 0·5 (–0·6 to 1·6, p=0·351)
Pain and impact of disability§
GMFCS level II 35·8 (17·8), n=51 23·9 (16·7), n=49 –1·7 ( –3·4 to 0·1, p=0·06)
GMFCS level III 36·8 (19·4), n=82 30·4 (16·8), n=78 –3·9 ( –6·1 to –1·8, p<0·0001)
All patients 36·4 (18·7), n=133 27·9 (17·0), n=127 –2·5 (–3·9 to –1·2, p<0·0001)
Family health¶
GMFCS level II 70·2 (19·6), n=51 79·9 (14·4), n=49 4·1 ( 2·2 to 5·9, p<0·0001)
GMFCS level III 67·9 (18·4), n=81 69·9 (19·8), n=79 0·7 ( –1·1 to 2·5, p=0·458)
All patients 68·8 (18·8), n=132 73·8 (18·5), n=128 2·0 (0·7 to 3·4, p=0·003)
SDR=selective dorsal rhizotomy. GMFM-66=66-item Gross Motor Function Measure. GMFCS=Gross Motor Function Classification System. CP-QoL=Cerebral Palsy Quality of Life 
Questionnaire. *There was evidence of an interaction between GMFCS level and GMFM-66 score (p=0·006). †GMFM-66 centiles are GMFCS level-specific and, therefore, no 
aggregated score is calculated. ‡Results are from the child primary caregiver or parent version. §No evidence of an interaction between GMFCS levels (p>0·05). ¶There was 
evidence of an interaction between GMFCS level and CP-QoL Child family health domain (p=0·0127). 
Table 2: Primary outcomes
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of spastic diplegia.4 The study was not designed to 
disentangle age effects or to extrapolate findings to 
children and young people of other ages or other GMFCS 
levels. There are also other unmeasurable factors, such 
as the quantity of physiotherapy received, which are 
confounders that cannot be accounted for. However, in 
this sense, our study reflects real-world clinical practice 
and provides a valuable picture of how the service would 
function and how patients would respond at least in the 
24 months after SDR. NHS England has recommended 
that physicians continue to capture outcomes on this 
cohort of children.
In conclusion, this multicentre prospective study 
provided assessed current SDR practice with a standardised 
Adverse event Concomitant 
medication
Outcome Additional information
Type Intensity or severity Related to SDR
Patient 1
Unknown Uncovered dystonia Mild Unknown Yes Not resolved Uncovered by SDR surgery
Patient 2
400 days Persisting dysaesthesia 
of feet and legs
Mild Definitely No Resolved Required hamstring lengthening 
24 months after SDR
Patient 3
30 days Wound infection Mild Definitely No Resolved ··
Patient 4
191 days Persisting dysaesthesia 
of feet and legs
Mild Definitely No Resolved Treated with dabapentin
Patient 5
2 days Diarrhoea and vomiting Mild Unlikely No Resolved Patient isolated and recovered 
quickly
Patient 6
1 day Constipation Mild Unlikely No Resolved with 
laxative
Related to pain medication
Patient 7
22 days Wound infection Mild Possible or likely Yes Resolved Resolved with antibiotic 
treatment
Patient 8
Unknown Persisting dysaesthesia of 
feet and legs
Mild Possible or likely No Not resolved Hypersensitivity in right foot
Patient 9
Unknown Back pain Mild Possible or likely Unknown Resolved ··
Patient 10
6 days Wound infection Mild Definitely No Resolved ··
Patient 11
55 days Urgency Mild Unknown No Resolved ··
Patient 12
28 days Wound infection Mild Definitely No Resolved ··
Patient 13
64 days New weakness Mild Definitely No Resolved ··
Patient 14
1 day Urinary retention after 
removal of indwelling 
urinary catheter
Moderate Definitely No Resolved Also had previously implanted 
intrathecal baclofen pump 
removed at SDR surgery while 
tube remained in situ; catheter 
reinserted later
34 days Persisting dysaesthesia of 
feet and legs
Mild Definitely No Resolved ··
60 days Swelling reported under 
wound site after discharge
Mild Definitely No Resolved Intrathecal baclofen pump 
removed at surgery
Patient 15
Unknown Granulation of wound Mild Definitely Unknown Resolved ··
Durations of adverse events are shown. SDR=selective dorsal rhizotomy.
Table 3: Adverse events
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approach in 137 children and five centres. We could 
demonstrate consistent evidence of improvement in 
function beyond the expected trajectory of children with 
cerebral palsy not treated with SDR. This improvement in 
function was seen alongside clear improvement in quality 
of life, including pain reduction. The observed benefits 
were seen for children with GMFCS levels II and III 
cerebral palsy over a 2-year period and mirrored those 
reported in earlier RCTs. Finally, this study led directly to 
an interim national policy decision that SDR would be 
funded for eligible children with cerebral palsy in England 
from 2018.
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